ESC 2025: Vericiguat for patients with heart failure and reduced ejection fraction across the risk s

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum

VICTORIA and VICTOR Clinical Trials

📚 ESC 2025 Coverage: Bridging Stability and Severity: Vericiguat’s Role Expands in Heart Failure Therapy, by Dr. Taghavi, Fellowship of Heart Failure.